Skip to main content

Program Mission

Dr. Kim Kasow’s research interests involve improving outcomes for a pediatric patient who require hematopoietic stem cell transplantation for the possibility of long-term survival. These patients include those requiring autologous and allogeneic stem cell transplants, regardless of the stem cell source.

Our hematopoietic stem cell transplant research team participates in collaborative studies through the following consortiums: the Children’s Oncology Group (COG) , the Blood and Marrow Transplant Clinical Trials Network, and the Pediatric Blood and Marrow Transplant Consortium in order to help move the field of pediatric transplantation forward.

We are active members of the following consortiums offering clinical trials to patients with high-risk, relapsed and refractory malignancies:

Children's Oncology Group  

Program Leaders

Return to Top


Currently Open Clinical Trails

If you have any questions about open clinical trails, please .

Diagnosis Age Range Study Title
Less Severe Sickle Cell Disease 2 – 10 Years Old HLA Matched Related Hematopoietic Stem Cell Transplantation for Children with Less Severe Sickle Cell Disease: A Sickle Transplant Alliance for Research (STAR) Trial
Severe Sickle Cell Disease 15 – 40 Years Old A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease (STRIDE 2)
Any Hematological Malignancy Any Age A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units for Transplantation in Pediatric and Adult Patient with Hematologic Malignancies and Other Indications
ALL, ALLy, AML, CML, Juvenile Myelomonocytic Leukemia 0 – 22 Years Old Natural History and biology of Long-Term Late Effects Following Hematopoeitic Cell Transplant for Childhood Hematologic Malignancies
Sickle Cell Disease 3 – 20 Years Old Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: A Sickle Transplant Alliance for Research (STAR) Trial
MDS, CLL, All, TLLy, AML, ABL, AUL, 15 – 70 Years Old A Multicenter, Phase II trail of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophoshamide for Patients with Hematologic Malignancies
Epstien-Barr Virus-Associated Viremia and Diseases Any Age A Multicenter, Open Label, Phase 3 Trail of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Allogeneic Hematopoietic Cell Transplant (alloHCT) Patient with EBV-Associated Post-Transplant Lymphoproliferative Disease (EV-PTLD) after Failure of Rituximab
Epstien-Barr Virus-Associated Viremia and Diseases Any Age A Multicenter Expanded Access Protocol of ATA129 for Subjects with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies
Acute Leukemia, Myelodysplasia 1 – 65 Years Old A Randomzied, Multicenter, Pahse III Trial of Calcineruin Inhibitor-Free Intervention for Prevention of Graft-Versus-Host Disease (GVHD)

Return to Top


Below is a list of recent publications; for additional publications from Dr. Kasow, please click here.

  1. A trail of unrelated onor marrow transplantation for children with severe sickle cell disease. Shenoy, S., Eapen, M., Panepinto, J.A., Logan, B.R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A.E., Kasow, K.A., Leung, K., Andreansky, M., Bhatia, M., Dalal, J., Haines, H., Jaroscak, J., Lazarus, H.M., Levine, J.E., Krishnamurti, L., Margolis, D., Megason, G.C., Yu, L.C. Pulsipher, M.A., Gersten, I., DiFronzo, N., Horowitz, M.M., Walters, M.C., & Kamani, N.  (2016). Blood. 
  2. Long-term follow-up after reduced-intensity conditioning and stem cell transplantation for childhood nonmalignant disorders. Madden, L.M., Hayashi, R.J., Chan, K.W., Pulsipher, M.A., Douglas, D., Hale, G.A., Chaudhury, S., Haut, P., Kasow, K.A., Gilman, A.L., Murray, L.M. & Shenoy, S. (2016). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation.
  3. Sequential renal and bone marrow transplants in a child with Fanconi anemia. Vincent, C.L., Primack, W.A., Hipps, J. & Kasow, K.A. Pediatric Transplantation. 
  4. Using fludarabine to reduce exposure to aklylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: Results of a dose de-escalation trail. Horan, J.T., Haight, A., Dioguardi, J.L. Brown, C., Grizzle, A., Shelman, C., Kanter, J., Hale, G., Nieder, M., Benton, M, Kasow, K.A., Abraham, A. & Chiang, K.Y. (2015). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 
  5. Through the eyes of young sibling donors: The hematopoietic stem cell donation experience. D’Auria, J.P, Fitzgerald, T.M, Presler, C.M. & Kasow, K.A. (2015). Journal of Pediatric Nursing.
  6. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Ringden, O., Brazauskas, R., Wang, Z., Ahmed, I., Atsuta, Y., Buchbinder, D., Burns, L.J., Cahn, J.Y., Duncan, C., Hale, G.A., Halter, J., Hayashi, R.J., Hsu, J.W., Jacobsohn, D.A., Kamble, R.T., Kamani, N.R., Kasow, K.A., Khera, N., Lazarus, H.M., Loren, A.W., Marks, D.I., Myers, K.C., Ramanathan, M., Saber, W., Savani, B.N., Schouten, H.C., Socie, G., Sorror, M.L., Steinberg, A., Popat, U., Wingard, J.R., Mattsson, J. & Majhail, N.S. (2014). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation.

Return to Top